New Orleans, LA
December 12-15, 2026
Booth #3057
Connect with Caris Life Sciences at ASH 2026
Join Caris Life Sciences® at the American Society of Hematology (ASH) Annual Meeting 2026 in New Orleans, Louisiana. Visit our team at booth #3057 to discover the latest innovations in precision medicine and explore new Caris research.
One Test. One Report. A Clearer Path to Myeloid Diagnostics.
Myeloid malignancies are complex; genetic testing doesn’t have to be. Using high-coverage Whole Genome Sequencing (WGS), Caris ChromoSeq replaces the genetic testing portion of the diagnostic workflow for myeloid malignancies, synthesizing multiple test results into one actionable, easy-to-read report. Learn more during ASH 2026.
Every Patient with Cancer Deserves Complete Answers
Caris helps physicians make more informed treatment decisions throughout the cancer care journey by providing high-quality molecular information to guide precise and individualized treatment decisions.
Learn more about how Caris testing can provide more actionable targets for more informed decisions to support more personalized care. Schedule time to meet with our team during ASH 2026 by completing the request form.
Schedule a Meeting
Products At-a-Glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure® delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Cancer Seek
MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric (ages 1-22) patients.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.